GLOBUS MEDICAL INC GMED
Globus Medical, Inc. (together, as applicable, with its consolidated subsidiaries, "Globus," the "Company," "we," "us" or "our"), headquartered in Audubon, Pennsylvania, is a medical device company that develops and commercializes healthcare solutions whose mission is to improve the quality of life of patients with musculoskeletal disorders. Founded in 2003, Globus is committed to medical device innovation and delivering exceptional service to hospitals, ambulatory surgery centers and physicians to advance patient care and improve efficiency. Since inception, Globus has listened to the voice of the surgeon to develop practical solutions and products to help surgeons effectively treat patients and improve lives.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.94B | $2.52B | $1.57B | $1.02B | $958.1M | $789.0M | $785.4M | $713.0M | $636.0M | $564.0M |
| Cost of revenue | $957.8M | $1.04B | $548.2M | $263.7M | $239.2M | $217.5M | $180.0M | $159.4M | $150.5M | $134.7M |
| Gross profit | $1.98B | $1.48B | $1.02B | $759.1M | $718.9M | $571.6M | $605.4M | $553.6M | $485.5M | $429.3M |
| R&D | $147.2M | $163.8M | $124.0M | $73.0M | $97.3M | $84.5M | $60.1M | $55.5M | $43.7M | $44.5M |
| SG&A | $1.18B | $981.4M | $643.8M | $432.1M | $408.1M | $354.8M | $354.8M | $311.6M | $267.8M | $222.2M |
| Total operating expenses | — | — | $887.2M | $531.2M | $546.9M | $460.1M | $433.4M | $384.2M | $323.7M | $275.1M |
| Operating income | $479.8M | $166.0M | $133.1M | $228.0M | $172.0M | $111.4M | $172.0M | $169.3M | $161.8M | $154.1M |
| Interest expense | — | $4.2M | $20.1M | $14.2M | $9.3M | $14.0M | $17.4M | $13.3M | $6.6M | $3.1M |
| Pre-tax income | $605.1M | $120.7M | $165.4M | $243.0M | $180.4M | $125.9M | $189.9M | $188.6M | $169.9M | $157.3M |
| Income tax | $67.2M | $17.7M | $42.5M | $52.9M | $31.2M | $23.6M | $34.7M | $32.1M | $62.6M | $52.9M |
| Net income | $537.9M | $103.0M | $122.9M | $190.2M | $149.2M | $102.3M | $155.2M | $156.5M | $107.3M | $104.3M |
| EPS, basic | 3.98 | 0.76 | 1.09 | 1.89 | 1.48 | 1.04 | 1.57 | 1.60 | 1.12 | 1.09 |
| EPS, diluted | 3.92 | 0.75 | 1.07 | 1.85 | 1.44 | 1.01 | 1.52 | 1.54 | 1.10 | 1.08 |
| Shares, diluted (wtd. avg.) | $137.1M | $137.9M | $114.6M | $102.6M | $103.6M | $101.0M | $102.0M | $101.3M | $97.9M | $96.4M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $526.2M | $784.4M | $467.3M | $150.5M | $193.1M | $239.4M | $195.7M | $139.7M | $118.8M | $67.0M |
| Short-term investments | $31.1M | $105.6M | $50.5M | $295.6M | $250.4M | $187.3M | $115.8M | $199.9M | — | — |
| Receivables | $678.9M | $557.7M | $503.2M | $213.2M | $164.4M | $141.7M | $154.3M | $137.1M | $116.7M | $92.0M |
| Inventory | $759.3M | $659.2M | $848.1M | $299.0M | $237.0M | $229.2M | $196.3M | $131.3M | $108.4M | $112.7M |
| Total current assets | $2.13B | $2.18B | $1.92B | $983.3M | $864.5M | $821.8M | $687.5M | $630.7M | $620.3M | $513.8M |
| Property, plant and equipment | $564.5M | $561.9M | $586.9M | $243.7M | $221.1M | $216.9M | $199.8M | $171.9M | $143.2M | $124.2M |
| Goodwill | $1.44B | $1.43B | $1.43B | $197.5M | $179.7M | $156.7M | $128.8M | $123.7M | $123.9M | $105.9M |
| Other intangibles | $745.1M | $795.1M | $924.6M | $63.6M | $68.7M | $86.9M | $78.8M | $87.3M | $78.7M | $61.7M |
| Total assets | $5.30B | $5.25B | $5.09B | $2.08B | $1.96B | $1.68B | $1.53B | $1.30B | $1.08B | $927.6M |
| Accounts payable | $98.9M | $75.1M | $56.7M | $36.1M | $22.0M | $18.2M | $24.6M | $25.9M | $25.0M | $17.5M |
| Total current liabilities | $498.5M | $855.9M | $392.3M | $159.2M | $140.2M | $120.8M | $111.4M | $96.1M | $93.1M | $79.9M |
| Total liabilities | $729.5M | $1.07B | $1.09B | $229.8M | $215.9M | $173.2M | $129.6M | $115.2M | $110.7M | $95.6M |
| Retained earnings | $1.39B | $1.15B | $1.14B | $1.24B | $1.19B | $1.05B | $1.05B | $892.7M | $736.2M | $628.9M |
| Total equity | $4.57B | $4.18B | $4.00B | $1.85B | $1.74B | $1.51B | $1.40B | $1.19B | $967.8M | $832.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $753.4M | $520.6M | $243.5M | $178.5M | $276.3M | $198.8M | $172.0M | $181.6M | $159.1M | $147.8M |
| Depreciation and amortisation | $276.8M | $253.4M | $145.5M | $68.3M | $69.9M | $62.9M | $52.7M | $41.6M | $42.1M | $38.8M |
| Stock-based compensation | $49.8M | $54.2M | $52.7M | $32.8M | $30.6M | $27.1M | $26.1M | $21.9M | $14.7M | $11.4M |
| Capital expenditure | $164.7M | $115.4M | $78.3M | $74.0M | $56.9M | $63.7M | $70.8M | $59.7M | $51.3M | $40.9M |
| Investing cash flow | -$355.0M | -$176.1M | $303.0M | -$110.4M | -$375.9M | -$117.3M | -$140.3M | -$193.0M | -$111.3M | -$162.7M |
| Financing cash flow | -$679.2M | -$27.7M | -$231.8M | -$110.0M | $54.1M | -$38.7M | $24.4M | $32.6M | $1.6M | $470.0K |
| Buybacks | $300.5M | $85.8M | $225.6M | $144.5M | — | $104.7M | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-027196.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |